EUCTR2007-000912-97-DE进行中（未招募）不适用
Phase II Trial of Pemetrexed in Second Line Advanced/Metastatic Osteosarcomas - N/A
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •[1] Histological diagnosis of high grade locally advanced or metastatic osteosarcoma (WHO classification), not amenable to surgery, radiation, or combined modality therapy with curative intent.
- •[2] One prior chemotherapy regimen for advanced disease; neo-adjuvant is not counted towards this requirement. Pemetrexed is considered as second line chemotherapy for advanced/metastatic disease.
- •[3] At least one unidimensionally measurable lesion meeting RECIST criteria (at least 10 mm in longest diameter by spiral computerized tomography [CT] scan, or at least 20 mm by standard techniques). Positron emission tomography [PET] scans and ultrasounds may not be used.
- •At least one measurable lesion outside of the field of any prior radiation therapy (according to RECIST criteria). Prior radiotherapy to a single index lesion is not allowed.
- •Osseous lesions with soft tissue tumor at study entry (excluding completely calcified or necrosed lesion) are considered measurable lesions.
- •[4] Have a performance status of 0, 1, or 2 on the ECOG scale
- •[5] Adequate organ function including the following:
- •Adequate bone marrow reserve: absolute neutrophil (segmented and bands) count (ANC) =1.0 x 10e9/L, platelets =100 x 10e9/L (in case of bone marrow disease: =75 x 10e9/L), and hemoglobin =9.0g/dL.
- •Hepatic: bilirubin < or = 1.5 times the upper limit of normal (x ULN), alkaline phosphatase (AP), aspartate transaminase (AST), and alanine transaminase (ALT) < or = 3.0 x ULN (AP, AST, and ALT < or = 5 x ULN is acceptable if the liver has tumor involvement).
- •Renal: calculated creatinine clearance (CrCl) =45 mL/min based on the standard Cockcroft and Gault formula.
- •[6] Estimated life expectancy of at least 12 weeks.
- •[7] Patient compliance and geographic proximity that allow adequate follow-up.
- •[8] Prior radiation therapy allowed to <25% of the bone marrow. Prior radiotherapy must be completed at least 4 weeks before study enrollment. Patients must have recovered from the acute toxic effects of the treatment prior to study enrollment.
- •[9] Patients must sign an informed consent document.
- •[10] Patients must be at least 18 years of age.
- •[11] Fully recovered from any previous surgery and prior chemotherapy (at least 4 weeks since major surgery or prior myelosuppressive chemotherapy). With the exception of alopecia, patients must have resolution of all acute toxic effects of any prior surgery or chemotherapy to NCI-CTC (Version 3.0) grade = 1.
- •[12] For women: Must be surgically sterile, post-menopausal, or compliant with a medically approved contraceptive regimen (for example, intrauterine device [IUD], birth control pills, or barrier device) during and for 6 months after the treatment period; must have a negative serum or urine pregnancy test within 7 days before study enrollment and must not be breast-feeding.
- •For men: Must be surgically sterile, or compliant with a contraceptive regimen during and for 6 months after the treatment period.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •[13] Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
- •[14] Have previously completed or withdrawn from this study or any other study investigating pemetrexed.
- •[15] Inability to comply with protocol or study procedures.
- •[16] Have a serious concomitant systemic disorder (e.g. active infection including HIV) that, in the opinion of the investigator, would compromise the patient’s safety or the patient’s ability to adhere to the protocol.
- •[17] Have a serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease, as defined by the New York Heart Association Class III or IV.
- •[18] Have a concurrent serious infection.
- •[19] Have a psychiatric disorder that prevents patients from providing informed consent or following protocol instructions. No other severe medical illness, including psychosis and previous history of severe cardiovascular disease.
- •[20] Have a prior malignancy other than osteosarcoma, carcinoma in situ of the cervix, or nonmelanoma skin cancer, unless that prior malignancy was diagnosed and definitively treated at least 5 years previously with no subsequent evidence of recurrence. Patients with a history of low grade (Gleason score < or = 6) localized prostate cancer will be eligible even if diagnosed less than 5 years previously.
- •[21] Have central nervous system (CNS) metastases (unless the patient has completed successful local therapy for CNS metastases and has been off corticosteroids for at least 4 weeks before starting study therapy). A screening computerized tomography (CT) or magnetic resonance imaging (MRI) before enrollment in the absence of a clinical suspicion of brain metastases is not required.
- •[22] Presence of clinically detectable (by physical exam) third-space fluid collections, for example, ascites or pleural effusions that can not be controlled by drainage or other procedures prior to study entry.
- •[23] Significant weight loss (that is =20%) over the previous 6 weeks before study entry.
- •[24] Concurrent administration of any other antitumor therapy.
- •[25] Inability to discontinue administration of aspirin at a dose >1.3 g/day or other nonsteroidal anti-inflammatory agents for 2 days before, the day of, and 2 days after the dose of pemetrexed (5 days prior for long-acting agents such as piroxicam).
- •[26] Inability or unwillingness to take folic acid or vitamin B12 supplementation.
- •[27] Inability to take corticosteroids.
- •[28] Pregnant or breast-feeding.
- •[29] Have had a recent (within 30 days of study treatment) or concurrent yellow fever vaccination.
研究者
相似试验
进行中（未招募）
1 期
Phase II Trial of Pemetrexed in Second Line Advanced/Metastatic Osteosarcomas - N/AAdvanced/Metastatic OsteosarcomaMedDRA version: 9.1Level: PTClassification code 10031294Term: Osteosarcoma metastaticEUCTR2007-000912-97-FREli Lilly and Company Limited32
进行中（未招募）
不适用
Phase II Trial of Pemetrexed in Second Line Advanced/Metastatic Osteosarcomas - N/AAdvanced/Metastatic OsteosarcomaMedDRA version: 9.1Level: PTClassification code 10031294Term: Osteosarcoma metastaticEUCTR2007-000912-97-GBEli Lilly and Company Limited32
进行中（未招募）
不适用
Phase II Trial of Pemetrexed in Second Line Advanced/Metastatic Osteosarcomas - NDAdvanced/metastatic osteosarcomasMedDRA version: 9.1Level: LLTClassification code 10031294Term: Osteosarcoma metastaticEUCTR2007-000912-97-ITELI LILLY32
进行中（未招募）
1 期
Phase II Trial of Pemetrexed in Second Line Advanced/Metastatic Osteosarcomas Estudio fase II con pemetrexed como tratamiento en segunda línea del osteosarcoma avanzado/metastásico - N/Aosteosarcoma avanzado/metastásicoMedDRA version: 9.1Level: PTClassification code 10031294Term: Osteosarcoma metastaticEUCTR2007-000912-97-ESilly S.A.32
招募中
2 期
Phase II study of pemetrexed for advanced or relapsed non-squamous non-small-cell lung cancer in elderly patientson-squamous non-small cell lung cancer in elderly chemo-naive patientsJPRN-UMIN000004018Juntendo University30